Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relative Bioavailability of LY4065967 Formulations in Healthy Participants
NCT07607483Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2026
- Primary completion
- Jul 2026
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of LY4065967 (3 arms), sponsored by Eli Lilly and Company. Primary endpoints: Maximum Concentration at Day 17, Area Under the Concentration Versus Time Curve from Time Zero to Time t at Day 17 and 1 more. Started Jun 2026; status: completed.
02
Drugs
LY4065967
Beyond the preview
Go deeper on NCT07607483.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07607483.